## Tadashi Terui

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2526516/publications.pdf

Version: 2024-02-01

84 papers 1,804 citations

394390 19 h-index 302107 39 g-index

84 all docs 84 docs citations

84 times ranked 2078 citing authors

#	Article	IF	CITATIONS
1	Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. Journal of Allergy and Clinical Immunology, 2014, 134, 622-633.e9.	2.9	283
2	Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of <scp>GPP</scp> . Journal of Dermatology, 2018, 45, 1235-1270.	1.2	159
3	Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Archives of Dermatological Research, 2003, 295, S43-S54.	1.9	123
4	Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. Journal of the American Academy of Dermatology, 2020, 82, 117-122.	1.2	120
5	Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis. JAMA Dermatology, 2018, 154, 309.	4.1	84
6	Significantly High Levels of Anti-dsDNA Immunoglobulin E in Sera and the Ability of dsDNA to Induce the Degranulation of Basophils from Chronic Urticaria Patients. International Archives of Allergy and Immunology, 2013, 161, 154-158.	2.1	79
7	Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis. JAMA Dermatology, 2019, 155, 1153.	4.1	66
8	Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. Journal of Dermatological Science, 2020, 98, 13-19.	1.9	63
9	Japanese guidance for use of biologics for psoriasis (the 2019 version). Journal of Dermatology, 2020, 47, 201-222.	1.2	58
10	Japanese guidance for use of biologics for psoriasis (the 2013 version). Journal of Dermatology, 2013, 40, 683-695.	1.2	53
11	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatology and Therapy, 2020, 10, 133-150.	3.0	51
12	Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective postâ€marketing surveillance. Journal of Dermatology, 2016, 43, 767-778.	1.2	37
13	<i><scp>HLA</scp> *12:02</i> is a susceptibility factor in lateâ€onset type of psoriasis in Japanese. Journal of Dermatology, 2014, 41, 697-704.	1.2	32
14	Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydropyridine receptor-mediated Ca2+ influx. Clinical Immunology, 2009, 131, 145-156.	3.2	30
15	Identification and analysis of an early diagnostic marker for malignant melanoma: ZAR1 intra-genic differential methylation. Journal of Dermatological Science, 2010, 59, 98-106.	1.9	29
16	Characteristics of Japanese patients with pustulotic arthroâ€osteitis associated with palmoplantar pustulosis: a multicenter study. International Journal of Dermatology, 2020, 59, 441-444.	1.0	29
17	Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis. Journal of Pharmacological Sciences, 2009, 110, 232-236.	2.5	23
18	Diagnostic histopathological features distinguishing palmoplantar pustulosis from pompholyx. Journal of Dermatology, 2019, 46, 399-408.	1.2	22

#	Article	IF	Citations
19	IL12B and IL23R gene SNPs in Japanese psoriasis. Immunogenetics, 2013, 65, 823-828.	2.4	21
20	Abrogation of High-Affinity IgE Receptor-Mediated Mast Cell Activation at the Effector Phase Prevents Contact Hypersensitivity to Oxazolone. Journal of Investigative Dermatology, 2010, 130, 725-731.	0.7	20
21	Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria. Allergology International, 2019, 68, 270-273.	3.3	19
22	Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Realâ€world evidence in Japan. Journal of Dermatology, 2021, 48, 175-183.	1.2	19
23	Aberrant Hypermethylation of Non-Promoter Zygote Arrest 1 (Zar1) in Human Brain Tumors. Neurologia Medico-Chirurgica, 2010, 50, 1062-1069.	2.2	17
24	Effectiveness of a heparinoidâ€containing moisturiser to treat senile xerosis. Australasian Journal of Dermatology, 2015, 56, 36-39.	0.7	17
25	Efficacy of guselkumab in a subpopulation with pustulotic arthroâ€osteitis through week 52: an exploratory analysis of a phase 3, randomized, doubleâ€blind, placeboâ€controlled study in Japanese patients with palmoplantar pustulosis. Journal of the European Academy of Dermatology and Venereology. 2020. 34. 2318-2329.	2.4	17
26	miR103a-3p in extracellular vesicles from Fcl $\mu$ RI-aggregated human mast cells enhances IL-5 production by group 2 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 2021, 147, 1878-1891.	2.9	16
27	Questionnaireâ€based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries. Journal of Dermatology, 2020, 47, 743-748.	1.2	16
28	Twentyâ€fourâ€week interim analysis from a phase 3 openâ€label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. Journal of Dermatology, 2019, 46, 745-751.	1.2	15
29	A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. European Journal of Dermatology, 2010, 20, 758-62.	0.6	13
30	A case of pemphigoid vegetans with autoantibodies against both BP180 and BP230 antigens. Journal of the American Academy of Dermatology, 2011, 64, 206-208.	1.2	12
31	Linear immunoglobulin A/G bullous dermatosis associated with ulcerative colitis. Journal of Dermatology, 2017, 44, 1295-1298.	1.2	12
32	Impact of ixekizumab treatment on skinâ€related personal relationship difficulties in moderateâ€toâ€severe psoriasis patients: 12â€week results from two Phase 3 trials. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1867-1875.	2.4	12
33	Longâ€term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Openâ€label phase 3 results. Journal of Dermatology, 2021, 48, 3-13.	1.2	12
34	Improved quality of life of patients with generalized pustular psoriasis in Japan: A crossâ€sectional survey. Journal of Dermatology, 2021, 48, 203-206.	1.2	12
35	Epidermal iron metabolism for iron salvage. Journal of Dermatological Science, 2017, 87, 101-109.	1.9	11
36	Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5Âyears in a randomized phase 3 study. Journal of Dermatology, 2021, 48, 1838-1853.	1.2	11

#	Article	IF	CITATIONS
37	Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to Fcl‰Rl stimulation in patients with chronic spontaneous urticaria. Asia Pacific Allergy, 2020, 10, e12.	1.3	11
38	Coexistence of papuloerythroderma of Ofuji and acrokeratosis paraneoplastica (Bazex syndrome) preceding the diagnosis of primary hepatocellular carcinoma. International Journal of Dermatology, 2011, 50, 1393-1396.	1.0	10
39	The oncogenic role of GASC1 in chemically induced mouse skin cancer. Mammalian Genome, 2015, 26, 591-597.	2.2	10
40	Immunohistochemical expression of podoplanin in so-called hard ^ ^alpha;-keratin-expressing tumors, including calcifying cystic odontogenic tumor, craniopharyngioma, and pilomatrixoma. Journal of Oral Science, 2012, 54, 165-175.	1.7	9
41	Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells. Allergology International, 2015, 64, S11-S17.	3.3	9
42	Differentiation between control subjects and patients with chronic spontaneous urticaria based on the ability of anti-IgE autoantibodies (AAbs) to induce FclµRI crosslinking, as compared to anti-FclµRIl± AAbs. Allergology International, 2019, 68, 342-351.	3 <b>.</b> 3	9
43	Comparative study of cytokeratin and langerin expression in keratinized cystic lesions of the oral and maxillofacial regions. Journal of Oral Science, 2015, 57, 287-294.	1.7	8
44	A Case of Linear IgA/IgG Bullous Dermatosis with Anti-laminin-332 Autoantibodies. Acta Dermato-Venereologica, 2015, 95, 359-360.	1.3	8
45	Realâ€world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12â€week interim analysis of postâ€marketing surveillance in Japan. Journal of Dermatology, 2022, 49, 411-421.	1.2	8
46	Gold activates mast cells via calcium influx through multiple H2O2-sensitive pathways including L-type calcium channels. Free Radical Biology and Medicine, 2011, 50, 1417-1428.	2.9	7
47	Non-promoter hypermethylation of zygote arrest 1 (ZAR1) in human brain tumors. Brain Tumor Pathology, 2011, 28, 199-202.	1.7	7
48	Dermatofibrosarcoma Protuberans on the Chest with a Variety of Clinical Features Masquerading as a Keloid: Is the Disease Really Protuberant?. Annals of Dermatology, 2014, 26, 643.	0.9	7
49	A Case of Sporotrichosis Caused by <i>Sporothrix globosa</i> in Japan. Annals of Dermatology, 2016, 28, 251.	0.9	7
50	Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatology and Therapy, 2022, 12, 1431-1446.	3.0	7
51	A novel splicing variant of CADM2 as a protective transcript of psoriasis. Biochemical and Biophysical Research Communications, 2011, 412, 626-632.	2.1	6
52	Differentiation and Apoptosis in Pilomatrixoma. American Journal of Dermatopathology, 2011, 33, 60-64.	0.6	6
53	A Case of Cutaneous Mastocytosis in a Child with Prominent Langerhans Cell Infiltration. Pediatric Dermatology, 2011, 28, 412-415.	0.9	6
54	Improvement of crow's feet lines by topical application of 1-carbamimidoyl-L-proline (CLP). European Journal of Dermatology, 2013, 23, 195-201.	0.6	6

#	Article	IF	CITATIONS
55	Quantitative Analysis of Formaldehyde-induced Fluorescence in Paraffin-embedded Specimens of Malignant Melanomas and Other Melanocytic Lesions. Acta Dermato-Venereologica, 2016, 96, 309-313.	1.3	5
56	Infantile linear IgA/IgG bullous dermatosis. European Journal of Dermatology, 2016, 26, 96-98.	0.6	5
57	Case of anaphylaxis due to carmellose sodium. Journal of Dermatology, 2020, 47, e15-e17.	1.2	5
58	Guselkumab improves joint pain in patients with pustulotic arthroâ€osteitis: A retrospective pilot study. Journal of Dermatology, 2021, 48, 199-202.	1.2	5
59	Serum level of hemokinin-1 is significantly lower in patients with chronic spontaneous urticaria than in healthy subjects. Allergology International, 2021, 70, 480-488.	3.3	4
60	Electron microscopic observation of cholesterotic fibrous histiocytoma of the finger. Journal of Dermatology, 2015, 42, 923-924.	1.2	3
61	Overall Impairment of Quality of Life in Japanese Patients with Hidradenitis Suppurativa: Comparison with National Standard. Acta Dermato-Venereologica, 2021, 102, adv00632.	1.3	3
62	FcR <i><math>\hat{I}^3</math></i> promotes contact hypersensitivity to oxazolone without affecting the contact sensitisation process in B6 mice. Experimental Dermatology, 2015, 24, 204-208.	2.9	2
63	Case of localized cutaneous nocardiosis caused by <i>Nocardia cyriacigeorgica</i> . Journal of Dermatology, 2019, 46, e452-e454.	1.2	2
64	A case of contact dermatitis caused by a polyurethane hot melt adhesive. Contact Dermatitis, 2019, 81, 389-391.	1.4	2
65	Erythematous lesion with peripheral purpura on the face. Clinical and Experimental Dermatology, 2019, 44, 428-431.	1.3	2
66	Rapid recurrence of dermatofibrosarcoma protuberans after initiation of adalimumab therapy in a patient with ankylosing spondylitis. Journal of Dermatology, 2020, 47, e244-e246.	1.2	2
67	Patients who have anti-FclµRI nonreactive basophils do not represent patients with severe chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 824-825.e2.	3.8	2
68	Disseminated <i>Mycobacterium massiliense</i> skin infection in an immunocompromised patient requiring longâ€term treatment. Journal of Dermatology, 2021, 48, e201-e202.	1.2	2
69	Autoantibodies against multiple epitopes in bp180 and laminin gamma-1 in subepidermal blistering skin disease associated with psoriatic erythroderma. Indian Journal of Dermatology, 2015, 60, 521.	0.3	2
70	Case of anaphylaxis due to lotus root. Journal of Dermatology, 2020, 47, e227-e228.	1.2	1
71	Mucosaâ€predominant pemphigus vulgaris with antiâ€desmocollin 2 and 3 antibody positivity and ocular symptoms. Clinical and Experimental Dermatology, 2021, 46, 1590-1592.	1.3	1
72	Retrospective study of the differences in the management for pustulotic arthroâ€osteitis in patients with palmoplantar pustulosis between dermatologists and rheumatologists. Journal of Dermatology, 2021, 48, e551-e553.	1.2	1

#	Article	IF	Citations
73	Aggressive CD4–CD8–CD45RA+CCR10– Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report. Acta Dermato-Venereologica, 2019, 99, 1176-1177.	1.3	1
74	Verrucous nevoid melanoma with satellite lesions on the scalp of a young man. International Journal of Dermatology, 2015, 54, 1291-1293.	1.0	0
75	Treatment of murine mast cells with IgEΰ and protein L enhances apoptotic cell death induced by IL-3 withdrawal. Biochemical and Biophysical Research Communications, 2015, 456, 700-705.	2.1	0
76	Disulfide-linked dimerization of the FcR $\hat{l}^3$ chain is required for positive and negative regulation of mast cell activation via Fc $\hat{l}\mu$ RI. Allergology International, 2017, 66, S41-S43.	3.3	0
77	Leiomyomatosis developed in a patient of neurofibromatosis type $1$ with fumarate hydratase gene mutation. Journal of Dermatology, 2019, 46, e456-e457.	1.2	0
78	Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer. European Journal of Dermatology, 2021, 31, 100-101.	0.6	0
79	Peripheral arthritis presenting pencilâ€inâ€cup deformity in a patient with palmoplantar pustulosis. Journal of Dermatology, 2021, 48, e612-e613.	1.2	0
80	Pathogenesis of Psoriasis Vulgaris (the second part). Nishinihon Journal of Dermatology, 2006, 68, 527-531.	0.0	0
81	Pathogenesis of Psoriasis Vulgaris (the third part). Nishinihon Journal of Dermatology, 2006, 68, 656-664.	0.0	0
82	Benefit of Proactive Therapy Using Topical Steroid for Atopic Dermatitis. Nishinihon Journal of Dermatology, 2014, 76, 598-605.	0.0	0
83	Mechanisms of Action, Efficacy and Side Effects of Nivolumab and Its Therapeutic Use at Itabashi Hospital, Nihon University School of Medicine. Journal of the Nihon University Medical Association, 2016, 75, 156-160.	0.0	0
84	English version of guidelines for the management of asteatosis 2021 in Japan. Journal of Dermatology, 2022, 49, .	1.2	0